| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785731 | Cancer Treatment and Research Communications | 2018 | 18 Pages |
Abstract
CK19 mRNA expression and CTC count appeared clinically meaningful in pretreated patients with MBC, even when adjusted for phenotype and visceral disease involvement. These results support the use of CK19 and CTC as relevant biomarkers for predicting clinical response in MBC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
S. Morales, A. Velasco, A. Gasol, F. Córdoba, J. Vidal, A. Serrate, J. Valls, J.C. Samame, R. Gisbert, D. Moral, A. Llombart-Cussac, A. Salud, X. Matias-Guiu,